ArticleESMO open2023

Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101.

Y Tomita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.